The mice model market involves the global biomedical and biotechnology sector focused on the development, breeding, and distribution of laboratory mice for scientific research. It primarily serves pharmaceutical companies, biotechnology firms, and research institutions to facilitate drug discovery, disease modeling, and preclinical safety and efficacy testing.
The global mice model market was valued at USD 1.53 billion in 2024 and reached USD 1.70 billion in 2025, and it is projected to reach USD 2.74 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
The mice model market is primarily driven by the high adoption of mice models in preclinical studies due to their genetic and physiological versatility, growing demand for mouse clinical trials (MCTs), and rapid advancements in genetic engineering technologies like CRISPR. However, market expansion is heavily restrained by ethical concerns surrounding animal testing, high costs associated with developing and maintaining specialized strains, and strict regulatory compliance frameworks. Lucrative opportunities lie in the rising demand for disease-specific models, particularly in oncology and neurodegenerative research, alongside the increasing focus on personalized medicine and expanding biomedical infrastructure in the Asia-Pacific region. Despite these prospects, the industry faces key challenges, including biological limitations where mice may not perfectly replicate human disease physiology, and the accelerating development and adoption of alternative non-animal testing methods like in vitro assays and computer modeling.
The target customers for the mice model industry market primarily encompass pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and research institutions, with pharmaceutical firms holding the dominant share. These customers require highly reliable, genetically engineered, and humanized mouse models to advance drug discovery, toxicology testing, and specialized research in fields like oncology, immunology, and neurology. Their preferences strongly lean toward advanced technologies like CRISPR/Cas9, which compress model-generation timelines, alongside specialized breeding and genetic testing services that ensure translational validity and assay reproducibility. Purchasing behavior is heavily driven by expanding preclinical R&D pipelines, strategic academic-industry partnerships, and the availability of research funding or institutional budgets, with a critical focus on adhering to strict regulatory compliance frameworks to ensure the validation and acceptability of models in the drug development process.
Market entry, expansion, and profitability in the mice model industry market are heavily shaped by strict ethical standards and government regulations governing animal experimentation, which can restrict the pace of research, though regulatory support for preclinical testing helps streamline study approvals. Technologically, the market is being revolutionized by advancements in genetic engineering, most notably CRISPR/Cas9 technology, which drastically compresses model-generation timelines and enables the precise creation of complex, humanized, and disease-specific lines. Economically, sustained growth is fueled by escalating global R&D expenditures and substantial public and private funding for biomedical research, though profitability requires significant capital investments to establish advanced vivariums and specialized breeding infrastructure.
The mice model industry market is being rapidly shaped by the growing emphasis on precision medicine and advanced genetic engineering technologies, particularly CRISPR/Cas9, which continues to dominate the landscape by compressing model-generation timelines and lowering production costs. Emerging trends include a strong shift toward specialized, humanized mice models—such as constructs featuring human immune systems and gut microbiomes to improve translational accuracy in oncology and infectious disease research—alongside a rising demand for specialized CRO services and molecular confirmation via next-generation genetic testing. These trends are evolving swiftly, as evidenced by CRISPR technology commanding over 37% of the market share and expanding at a robust compound annual growth rate (CAGR) of 13.6%, while the overall market for genetically modified models is projected to drive steady double-digit growth rates reaching up to 10.13% through 2034.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
Technological innovations disrupting the mice model industry market are centered on genetic engineering, advanced disease replication, and computational integration. The industry is witnessing significant traction in the adoption of CRISPR/Cas9 gene-editing technology, which has revolutionized functional genomics by enabling the rapid, precise, and cost-effective generation of knockout, knock-in, and conditional mutant models. Furthermore, there is a major shift toward sophisticated humanized mouse models—such as genetically engineered mice with human-like telomeres—to better mimic human physiology for translational research in oncology, immunology, and aging. Additionally, the integration of artificial intelligence and machine learning is rapidly gaining momentum to optimize predictive modeling, analyze data, and enhance preclinical study outcomes.
In the mice model industry market, short-term hype and episodic fluctuations often surround immediate media or venture capital enthusiasm for early-stage experimental strains and niche testing fads that face unpredictable regulatory hurdles or public ethical scrutiny. Conversely, long-term structural shifts are firmly anchored in global biomedical R&D infrastructure, expanding oncology pipelines, and personalized medicine. These enduring transformations include the widespread clinical adoption of CRISPR/Cas9 and advanced gene-editing technologies to compress model-generation timelines, the rising institutional demand for humanized and disease-specific polygenic constructs with higher translational validity, and the steady integration of contract research organizations (CROs) into the standard preclinical drug discovery and safety assessment workflows.
Source:https://www.marketsandmarkets.com/Market-Reports/mice-model-market-1308.html
